Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat

In a phase II study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory to or intolerant of prior therapies. Significant molecular responses were achieved within 3-6 months in 81% of patients with phenotypic driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Leibundgut, Elisabeth Oppliger, Haubitz, Monika, Burington, Bart, Ottmann, Oliver G., Spitzer, Gary, Odenike, Olatoyosi, McDevitt, Michael A., Röth, Alexander, Snyder, David S., Baerlocher, Gabriela M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409045/
https://www.ncbi.nlm.nih.gov/pubmed/32732354
http://dx.doi.org/10.3324/haematol.2020.252817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409045/
https://www.ncbi.nlm.nih.gov/pubmed/32732354
http://dx.doi.org/10.3324/haematol.2020.252817

Ejemplares similares